Clinical research continues to evolve at an impressive pace. Digital technologies streamline data capture, biomarkers deepen biological insight, and innovative trial designs broaden access for diverse populations. These advances have unquestionably accelerated development and expanded participant reach. Still, across all this progress, one dimension consistently shapes outcomes yet remains underrepresented in planning, modeling, and oversight: patient behavior.   

Behavioral factors like motivation, adherence, expectancy, and engagement drive meaningful variability across therapeutic areas and study formats. Sponsors and CROs encounter their effects daily: adherence curves that dip unexpectedly; placebo responses that complicate endpoint interpretation; engagement patterns that shift with perceived burden or context (e.g., decentralized vs. sitebased). The influence of these human factors is visible and consequential, yet still not addressed with the same rigor as biological or operational variables.   

This recognition is one reason the field is turning attention to what Cognivia calls the behavioral intelligence layer a necessary complement to biological markers and operational intelligence. It is also why Cognivia’s CEO, Dominique Demolle, has been invited to speak at two upcoming industry events: the Fortrea Innovation & Technology Summit, an exploration of innovation in the emerging age of intelligence, and the SAPAGP Conference, a global forum for scientific exchange that spans scientific, clinical, and business tracks. Across both events, the underlying interest is the same: behavioral prediction is becoming essential to nextgeneration clinical innovation.   

Behavioral Variability: A Persistent Source of Trial Risk 

Even the most scientifically sound and operationally efficient protocols face challenges rooted in human behavior. Adherence rarely remains stable over an entire trial, participants’ motivation naturally fluctuates as personal circumstances or perceived burden shift, and placebo response can influence endpoints in ways unrelated to the investigational product. Crucially, these anomalies are recurring patterns reported across indications, trial models, and geographies. Their downstream impact is direct on data quality, retention, protocol deviations, and ultimately the statistical power and interpretability of results.  

When behavioral signals are ignored or treated as noise, they manifest as unpredictable variability. When measured and modeled early, they become actionable risk indicators that enable targeted intervention. In analysis, they can be incorporated as prespecified prognostic covariates that improve precision and power. 

From Insight to a Formal Scientific Layer 

For decades, behavioral influences were acknowledged but hard to quantify consistently. Today, validated psychometrics, structured behavioral constructs, and predictive modeling allow these factors to be measured with rigor and integrated into trial decisions. Positioned alongside RBM and operational intelligence behavioral data adds a complementary view rooted in patient experience and human variability. In practice, that means: 

• Quantifiable measurement through validated instruments; 
• Predictive value for adherence, engagement, and placebo response; 
• Robustness when effects are reproducible across studies and therapeutic areas.  

Recognizing the behavioral layer means acknowledging that behavior follows patterns that can be anticipated, monitored, supported, and incorporated analytically as covariates to increase precision.  

Behavioral Prediction for Clinical Research 

Behavioral prediction blends behavioral science with modern analytics to create measurable, interpretable variables that connect directly to endpoints and operational decisions. Rather than relying on punctual observations or qualitative impressions, it: 

• Captures drivers of motivation and adherence through validated constructs; 
• Aligns predictive modeling with clinical outcomes; 
• Produces interpretable outputs that clarify why  risk is emerging and where to act; 
• Guides patient and site support strategies; 
• Enables prespecified covariates that improve power and precision within the SAP particularly in placebosensitive conditions.   

Cognivia’s role is to translate these signals into reliable predictions that fit naturally into clinical workflows anticipating behavioral variability before it undermines timelines, data quality, or endpoints and to support statistically principled use of behavioral covariates.  

Scientific Rigor as the Foundation 

Behavioral prediction only creates value when the underlying science is solid. That’s why established good practices apply here as much as anywhere else: 

• Validated instruments that measure behavior relevant to clinical participation; 
• Multidimensional yet interpretable models that avoid blackbox opacity; 
• Transparent methods aligned with regulatory expectations and suitable for scientific review; 
• Interdisciplinary expertise bridging behavioral science, statistics, AI, and clinical operations.  

The payoff is practical: predictions become explainable insights clinicians and study teams can act on, not opaque algorithmic suggestions.  

 
Where AI Fits 

AI supports the behavioral layer, but it is not the story – the science is. Properly applied, AI/ML helps scale structured behavioral insights, detect subtle patterns over time, and align signals across sources. However, traditional AI/ML that analyzes historical data alone generally cannot predict adherence, expectancy, or motivation without the behavioral constructs that explain why  these patterns occur. Grounding models in structured behavioral science makes outputs more interpretable, clinically relevant, and trustworthy.  

Behavioral Signals and RBM: A Complementary Fit 

RiskBased Monitoring (RBM) excels at identifying operational risks such as site performance issues, data inconsistencies, and process deviations often via centralized monitoring and KRIs defined in ICH E6(R2) and subsequent FDA guidance. Yet classic RBM frameworks are frequently blind to humanfactor risks that emerge before operational flags appear.   

Integrating behavioral prediction with RBM closes that gap. Declining motivation, early adherence risk, expectancy effects, and engagement fluctuations can be surfaced as behavioral KRIs or central statistical monitoring contexts, enriching oversight with signals that are patientcentric and predictive. The result is: 

• More holistic risk detection, blending operational and behavioral indicators; 
• Earlier, more targeted interventions, directed where support is most needed; 
• Better patient experience with fewer preventable deviations.   

This union strengthens both operational control and humancentered support, particularly important as decentralized and hybrid models continue to expand.   

Why Conferences Are Focusing on the Behavioral Layer 

Across scientific and operational functions, teams are asking practical questions that signal a growing awareness of behavioral impact: 

• How can we anticipate adherence risk and design supportive touchpoints? 
• How do behavioral drivers shape treatment response or placebo response? 
• Where can behavioral insights strengthen site support? 
• Which statistical strategies (e.g., prespecified covariates) best address placebo response variability? 

Both Fortrea (with an innovation lens in the age of intelligence) and SAPAGP (with broad scientific and AIrelated tracks) will cove behavioral science and prediction as it is crossfunctional relevant to design, monitoring, analytics, and patient experience.   

A More Predictable, HumanCentric Future for Clinical Research 

The behavioral layer is an overlooked yet essential determinant of clinical success. When measured rigorously and modeled transparently, it transforms a persistent source of variability into a predictable, manageable, and patientcentric advantage. First, operationally through behavioral risk intelligence (e.g., Cognivia Signal) and then analytically through prespecified covariates (e.g., Placebell) that align with regulatory guidance and strengthen statistical power.   

Go Deeper (OnDemand Webinar) 

From Reactive Retention to Predictive Control: Using Behavioral Intelligence to Anticipate and Manage DropOut Risk in Clinical Trials. 

A practical walkthrough of how behavioral prediction supports trial predictability, data quality, and patient experience.